引 言
甲状腺癌以其发病率逐年增高日益引人关注,根据 2018 年国际癌症研究机构 (International Agency for Research on Cancer,IARC) 的数据估计,全球甲状腺癌发病率约为 6.7/10 万,我国每年新增病例达 19 万(194,232 例)[1]。分化型甲状腺癌(differentiated thyroid cancer,DTC)起源于甲状腺滤泡细胞,是甲状腺癌中最为常见的类型,主要包括乳头状癌、滤泡癌、Hürthle 细胞癌和低分化甲状腺癌,占甲状腺癌总体的 95% 以上。
1. TNM 分期
2. 复发危险度分层
3.动态评估
1.初次 131I 治疗
2.再次 131I 治疗
1.TSH 准备
2.低碘准备
3.育龄女性相关注意事项
4.患者一般状态评估
参考文献:
[1] FERLAY J, COLOMBET M, SOERJOMATARAM I, et al. Estimating the global cancer incidence and mortality in 2018: GLOBOCAN sources and methods[J]. Int J Cancer, 2019, 144(8): 1941-1953.
[2] KIM T H, KIM Y N, KIM H I, et al. Prognostic value of the eighth edition AJCC TNM classification for differentiated thyroid carcinoma[J]. Oral Oncol, 2017, 71: 81-86.
[3] MAZZAFERRI E L, JHIANG S M. Long-term impact of initial surgical and medical therapy on papillary and follicular thyroid cancer[J]. Am J Med, 1994, 97(5): 418-428.
[4] SHEN W T, OGAWA L, RUAN D, et al. Central neck lymph node dissection for papillary thyroid cancer: comparison of complication and recurrence rates in 295 initial dissections and reoperations[J]. Arch Surg, 2010, 145(3): 272-275.
[5] 中华医学会核医学分会. 131I 治疗分化型甲状腺癌指南(2014 版)[J]. 中华核医学与分子影像杂志, 2014, 34(4): 264-278.
[6] HAUGEN B R, ALEXANDER E K, BIBLE K C, et al. 2015 American Thyroid Association Management Guidelines for adult patients with thyroid nodules and differentiated thyroid cancer: the American Thyroid Association guidelines task force on thyroid nodules and differentiated thyroid cancer[J]. Thyroid, 2016, 26(1): 1-133.
[7] NASCIMENTO C, BORGET I, TROALEN F, et al. Ultrasensitive serum thyroglobulin measurement is useful for the follow-up of patients treated with total thyroidectomy without radioactive iodine ablation[J]. Eur J Endocrinol, 2013, 169(5): 689-693.
[8] HALL F T, BEASLEY N J, ESKI S J, et al. Predictive value of serum thyroglobulin after surgery for thyroid carcinoma[J]. Laryngoscope, 2003, 113(1): 77-81.
[9] KHEEMSTRA K A, LIU Y Y, STOKKEL M, et al. Serum thyroglobulin concentrations predict disease-free remission and death in differentiated thyroid carcinoma[J]. Clin Endocrinol (Oxf), 2007, 66(1): 58-64.
[10] RONGA G, FILESI M, VENTRONI G, et al. Value of the first serum thyroglobulin level after total thyroidectomy for the diagnosis of metastases from differentiated thyroid carcinoma[J]. Eur J Nucl Med, 1999, 26(11): 1448-1452.
[11] YANG X, LIANG J, LI TJ, et al. Postoperative stimulated thyroglobulin level and recurrence risk stratification in differentiated thyroid cancer[J]. Chin Med J, 2015, 128(8): 1058-1064.
[12] ZHAO T, LIANG J, LI T, et al. Serial stimulated thyroglobulin measurements are more specific for detecting distant metastatic differentiated thyroid cancer before radioiodine therapy[J]. Chin J Cancer Res, 2017, 29(3): 213-222.
[13] ZHAO T, LIANG J, LI T, et al. Value of serial preablative thyroglobulin measurements: can we address the impact of thyroid remnants?[J]. Nucl Med Commun, 2016, 37(6): 632-639.
[14] SEO J H, LEE S W, AHN B C, et al. Recurrence detection in differentiated thyroid cancer patients with elevated serum level of antithyroglobulin antibody: special emphasis on using (18)F-FDG PET/CT[J]. Clin Endocrinol, 2010, 72(4): 558-563.
[15] KIM W G, YOON J H, KIM W B, et al. Change of serum antithyroglobulin antibody levels is useful for prediction of clinical recurrence in thyroglobulin-negative patients with differentiated thyroid carcinoma[J]. J Clin Endocrinol Metab, 2008, 93(12): 4683-4689.
[16] 张 娜, 梁 军. 甲状腺乳头状癌 131I 清甲后甲状腺球蛋白抗体变化趋势及其与疗效的关系 [J]. 中华核医学与分子影像杂志, 2018, 38(3): 168-171.
[17] VERBURG F A, STOKKEL M P, DÜREN C, et al. No survival difference after successful (131)I ablation between patients with initially low-risk and high-risk differentiated thyroid cancer[J]. Eur J Nucl Med Mol Imaging, 2010, 37(2): 276-283.
[18] YIN Y, MAO Q, CHEN S, et al. A quantitative study about thyroid stunning after diagnostic whole-body scanning with 74 MBq 131I in patients with differentiated thyroid carcinoma[J]. Q J Nucl Med Mol Imaging, 2015, 59(4): 455-461.
[19] YAP B K, MURBY B. No adverse affect in clinical outcome using low preablation diagnostic (131)I activity in differentiated thyroid cancer: refuting thyroid-stunning effect[J]. J Clin Endocrinol Metab, 2014, 99(7): 2433-2440.
[20] ETCHEBEHERE E C, SANTOS A O, MATOS P S, et al. Is thyroid stunning clinically relevant? A retrospective analysis of 208 patients[J]. Arq Bras Endocrinol Metabol, 2014, 58(3): 292-300.
[21] WALRAND S, HESSE M, JAMAR F. Statistical and radiobiological analysis of the so-called thyroid stunning[J]. EJNMMI Res, 2015, 5(1): 67.
[22] CHEN L, LUO Q, SHEN Y, et al. Incremental value of 131I SPECT/CT in the management of patients with differentiated thyroid carcinoma[J]. J Nucl Med, 2008, 49(12): 1952-1957.
[23] AVRAM A M, ROSCULET N, ESFANDIARI N H, et al. Differentiated thyroid cancer outcomes after surgery and activity-adjusted 131I theragnostics[J]. Clin Nucl Med, 2019, 44(1): 11-20.
[24] VAN TOL K M, JAGER P L, DE VRIES E G, et al. Outcome in patients with differentiated thyroid cancer with negative diagnostic whole-body scanning and detectable stimulated thyroglobulin[J]. Eur J Endocrinol, 2003, 148(6): 589-596.
[25] LOU K, GU Y, HU Y, et al. Technetium-99m-pertechnetate whole-body SPET/CT scan in thyroidectomized differentiated thyroid cancer patients is a useful imaging modality in detecting remnant thyroid tissue, nodal and distant metastases before 131I therapy. A study of 416 patients[J]. Hell J Nucl Med, 2018, 21(2): 121-124.
[26] LIU M, CHAI L, LUO Q, et al. 99mTc-pertechnetate-avid metastases from differentiated thyroid cancer are prone to benefit from 131I therapy: a prospective observational study[J]. Medicine (Baltimore), 2017, 96(33): e7631.
[27] WAN Q, BAI L, ZHAO G, et al. Diagnostic performance of 18F-FDG-PET/CT in DTC patients with thyroglobulin elevation and negative iodine scintigraphy: a meta-analysis[J]. Eur J Endocrinol, 2019.[Epub Ahead of Print]
[28] FEINE U, LIETZENMAYER R, HANKE J P, et al. Fluorine-18-FDG and iodine-131-iodide uptake in thyroid cancer[J]. J Nucl Med, 1996, 37(9): 1468-1472.
[29] LIMA N, CAVALIERE H, TOMIMORI E, et al. Prognostic value of serial serum thyroglobulin determinations after total thyroidectomy for differentiated thyroid cancer[J]. J Endocrinol Invest, 2002, 25(2): 110-115.
[30] HAY I D, HUTCHINSON M E, GONZALEZ-LOSADA T, et al. Papillary thyroid microcarcinoma: a study of 900 cases observed in a 60-year period[J]. Surgery, 2008, 144(6): 980-987.
[31] ROSS D S, LITOFSKY D, AIN K B, et al. Recurrence after treatment of micropapillary thyroid cancer[J]. Thyroid, 2009, 19(10): 1043-1048.
[32] BAUDIN E, TRAVAGLI J P, ROPERS J, et al. Microcarcinoma of the thyroid gland: the Gustave-Roussy Institute experience[J]. Cancer, 1998, 83(3): 553-559.
[33] CREACH K M, SIEGEL B A, NUSSENBAUM B, et al. Radioactive iodine therapy decreases recurrence in thyroid papillary microcarcinoma[J]. ISRN Endocrinol, 2012, 2012: 816386
[34] LIN H W, BHATTACHARYYA N. Survival impact of treatment options for papillary microcarcinoma of the thyroid[J]. Laryngoscope, 2009, 119(10): 1983-1987.
[35] BRYAN R. HAUGEN, ERIK K, et al. 2015 American Thyroid Association management guidelines for adult patients with thyroid nodules and differentiated thyroid cancer: the American Thyroid Association guidelines task force on thyroid nodules and differentiated thyroid cancer[J]. Thyroid, 2016, 26(1): 1-133.
[36] WELLS K, MOREAU S, SHIN Y R, et al. Positive (+) post-treatment (tx) scans after the radioiodine (RAI) tx of patients who have ill- differentiated thyroid cancer (WDTC), positive serum thyroglobulin levels (TG+), and negative diagnostic (dx) RAI whole body scans (WBS-)[J]. J Nucl Med, 2008, 49: 238.
[37] SABRA M M, GREWAL R K, TALA H, et al. Clinical outcomes following empiric radioiodine therapy in patients with structurally identifiable metastatic follicular cell-derived thyroid carcinoma with negative diagnostic but positive post-therapy 131I whole-body scans[J]. Thyroid, 2012, 22(9): 877-883.
[38] DURANTE C, HADDY N, BAUDIN E, et al. Long-term outcome of 444 patients with distant metastases from papillary and follicular thyroid carcinoma: benefits and limits of radioiodine therapy[J]. J Clin Endocrinol Metab, 2006, 91(8): 2892–2899.
[39] PADOVANI R P, KASAMATSU T S, NAKABASHI C C, et al. One month is sufficient for urinary iodine to return to its baseline value after the use of water-soluble iodinated contrast agents in post-thyroidectomy patients requiring radioiodine therapy[J]. Thyroid, 2012, 22(9): 926-930.
[40] JONKLAAS J, SARLIS N J, LITOFSKY D, et al. Outcomes of patients with differentiated thyroid carcinoma following initial therapy[J]. Thyroid, 2006, 16(12): 1229-1242.
中国临床肿瘤学会甲状腺癌专业委员会,中国研究型医院学会分子诊断专业委员会甲状腺癌学组,医促会甲状腺疾病专业委员会核医学组,北京核医学分会治疗学组,北京市核医学质量控制和改进中心,北京精准放射医学学会核医学诊断治疗工作委员会
共识编写执笔专家(排名不分先后,按姓氏笔画为序,以下同):
丁 勇 马庆杰 王任飞 王叙馥
韦智晓 石 峰 石洪成 包建东
吕中伟 朱虹芸 李林法 李小东
李晓峰 杨 辉 杨爱民 张 青
陆克义 陈立波 陈文新 邵玉军
范 岩 林岩松 林承赫 赵文锐
高再荣 崔亚利 梁英奎 颜 兵
秘 书:
慕转转
审稿专家:
王 铁 安 锐 李思进 李亚明
李 方 李 林 张永学 蒋宁一
文章内容仅供医疗专业人士阅读
联系客服